Aarti Pharmalabs -
Q2 FY 25 results and concall highlights -
Revenues - 458 vs 439 cr, up 4 pc
EBITDA - 94 vs 88 cr, up 6 pc (margins @ 20.5 vs 20 pc)
PAT - 54 vs 52 cr, up 5 pc
Manufacturing footprint -
Dombivali -
Unit 1 - for APIs, Intermediates, CDMO
Vapi -
Unit -2 - for APIs, Intermediates, CDMO
Tarapur -
Unit -3 - for Xanthine and derivatives
Unit -4 - for APIs, CDMO
Unit -5 - for Xanthine and derivatives
Unit -6 - for Xanthine Intermediates
Atali -
New unit under construction for CDMO, intermediates
Revenue breakup for Q2 -
Xanthine Derivatives and allied products - 45 pc
APIs and Intermediates - 51 pc
CMO/CDMO - 4 pc ( it was 11 pc for full FY 24. This segment generally picks up pace in Q3 and Q4 )
Domestic : International sales @ 47 : 53
Xanthine derivatives business continues to witness stiff competition from China. Currently operating at peak capacity utilisations
Breakup of API sales -
43 pc regulated mkts
47 pc RoW mkts
10 pc Non Regulated mkts
Currently working on 55 CDMO projects with 19 customers. 28 projects are in commercial stages and 27 projects are in various stages of development
Some high value project deliveries are lined up for deliveries in the latter half of this FY ( may even spill over to next FY )
Expect the Atali project to commercialise in Q4
The expansion of Intermediates unit at Vapi unit is complete and is undergoing trial production
Company has successfully commissioned a Solar energy project at Akola. This should help save energy costs in a big way wef Q3
Seeing increased RFPs, enquiries from existing and new customers in the CMO/CDMO space. This should augur well for the company in the long term
The Xanthine spot mkt is very price competitive. However - the long term supply arrangements with big clients are price remunerative. Also, the Pharma applications of Xanthine derivatives mkt is also quite remunerative
Expect meaningful contribution from the new Atali site to flow through by FY 27 - as it takes to ramp up a Greenfield site
Top three therapies for company’s API business include - Anti Hypertensives, Corticosteroids and CNS. Top 3 API customers revenue contribution is around 20 pc for the company ( indicating low customer concentration )
Guiding for 20 pc + kind of growth in CDMO business this FY. Growth for next 2 FY’s should be even higher
Company currently commands 15 pc of world’s Xanthine capacity. Aprox 10 pc of world capacity is in Europe and the rest 75 pc is in China. Post the expansion of Xanthine facility ( sometime in Q3 FY 26 ), company should reach about 17-18 pc of world’s capacity ( @ aprox 9000 MT )
Guiding for a 15 pc kind of EBITDA growth CAGR for next 3 yrs ( company admits its a conservative guidance )
Company has 28 commercial molecules in their CDMO division. However their combined sales in FY 24 was < 200 cr. Actually, company is a relatively new entrant in this space. As time passes and innovators become more comfortable with the company, company is expected to get greater share of revenues for these products plus company is expected to commercialise more CDMO projects. Some of these projects / molecules may even go on to become quite large in future and company may get greater share of their manufacturing. Basically, in the CDMO segment - multiple positive optionalities can play out in future
Company’s segment wise gross margins vary from 35 to 65 pc. Lowest for Xanthine segment, highest for CDMO segment
Once the company comes up with added capacities of Xanthine, they intend to allocate a greater proportion of added capacity for Pharma applications in regulated mkts. That should improve the overall margin profile of the Xanthine derivatives segment
Disc: holding, biased, not SEBI registered, not a buy/sell